MedTrace Logo

Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

NCT04275388 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 426

Last updated 2020-05-20

No results posted yet for this study

Summary

the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.

Conditions

  • 2019 Novel Coronavirus Pneumonia

Interventions

DRUG

Xiyanping injection

Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,

DRUG

Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride

Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride

Sponsors & Collaborators

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2020-07-14
Completion
2021-12-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04275388 on ClinicalTrials.gov